BUFFALO, N.Y., Feb. 06, 2022 (GLOBE NEWSWIRE) — POP Biotechnologies (POP BIO), a biopharmaceutical startup, announces the approval of the plan for a Phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19 is a protein-based vaccine consisting of Eubiologics' protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the Spontaneous-Nanoliposome Antigen Particle (SNAP) technology of POP BIO. "This Phase III trial is a monumental step forward for our technology. Achieving this critical milestone provides validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform's development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide," says POP BIO President and cofounder Jonathan Smyth.
POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious disease and cancer through a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the stable particle-formation and liposome-display of protein and peptide antigens, resulting in substantial improvements in immune responses. According to Dr. Jonathan Lovell, technology inventor and POP BIO co-founder, "SNAP is a vaccine platform technology that could be applicable to any vaccine-related indication, for both chronic and infectious diseases. In-human testing for the COVID-19 vaccine will de-risk the technology for many other indications."
Eubiologics will be able to commence Phase III comparison trials for 4,000 healthy participants in the Philippines, Bangladesh, and other countries based on a standard comparison clinical trial guideline. Eubiologics will work closely with international research organizations for expedited recruitment in countries with low vaccination rates as well as the analysis of trial results to accelerate the regulatory approval and commercialization of EuCorVac-19. EuCorVac-19 has already proved its safety and efficacy in Phase I/II clinical trials, the results of which were announced in December 2021. Eubiologics expects to expedite the development of an Omicron variant vaccine based on the same platform used for EuCorVac-19. A company official said, "The company has already had product supply MOUs with partners in the Philippines and Saudi Arabia, and many Asian, CIS, Latin American partners have shown a great interest in EuCorVac-19. Once the product is launched, the company will target the overseas markets that have high population and middle-income based on the product's safety, efficacy, and logistics convenience."
POP BIO is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology is exclusively licensed from the SUNY-RF.
Eubiologics is a South Korean Biotechnology company that received funds for the Phase I/II EuCorVac-19 trial from the new drug development committee of the Korean Ministry of Health and Welfare and recently submitted the application for phase III trial to get additional financial assistance. Eubiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of the COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line, which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded.
For more information, contact: email@example.com
This content was issued through the press release distribution service at Newswire.com.
With its stock down 22% over the past three months, it is easy to disregard VEEM (ASX:VEE). But if you pay close…
In order to bring people closer together for the Olympic Winter Games Beijing 2022, despite the Covid restrictions and geographical distances between them, Alibaba has launched an innovative cloud-based technology "Cloud ME" powered by its real-time communication (RTC) solution. "Cloud ME" facilitates social interactions for people who are keen to explore bona fide meeting experiences during the Olympic Winter Games, enabling them to meet, and enjoy real-time conversations with each other via li
Stock markets largely steadied Monday with sentiment dominated by the outlook for interest rate rises as inflation soars.
Rinvoq was recently authorized in the U.S. as a treatment for patients with moderate-to-severe eczema.
The biggest coronavirus vaccine stocks posted explosive gains over the past couple of years. Vaccine leader Moderna (NASDAQ: MRNA) surged 1,200% over that time period. And latecomer Novavax (NASDAQ: NVAX) soared a mind-boggling 3,400%.
Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.
Dewpoint Therapeutics, a biomolecular condensates startup known for its partnerships with major pharmaceutical companies, has brought in $150 million as it marches toward the clinic.
In New York City in 1920 – nearly two years into a deadly influenza epidemic that would claim at least 50 million lives worldwide – the new year began on a bright note. "Best Health Report for City in 53 Years," boasted a headline in the New York Times on Jan. 4, 1920, after New York had survived three devastating waves of the flu virus. The nation as a whole, which would ultimately lose 675,000 people to the disease, believed that the end might finally be in sight.Subscribe to The Post Most new
Photo Illustration by Kristen Hazzard/The Daily Beast/GettyIn May 2020, I injured my ankle so badly I couldn’t move a toe. The slightest twitch sent a paralyzing bolt through my leg—like head-splitting microphone feedback that makes you recoil and cover your ears. That’s what back labor felt like—but in my spine.My baby was “sunny side up”—a vaguely appetizing term that meant his head was pushing against my spine. Every time I had a contraction, it felt like my back was breaking. The pain felt u
Just 3 in 10 parents of children under 5 say they’ll get their child vaccinated right away once a COVID-19 vaccine is approved for their age group, according to new survey findings published this month by KFF, a healthcare think tank. Parents are more willing to get their older children vaccinated: Just 33% of parents of 5- to 11-year-olds say their child has had at least one COVID-19 shot, though that’s up from 16% in November, while 61% of parents of 12- to 17-year-olds said their child had received at least one shot, up from just under 50% in November. This week, Pfizer and BioNTech asked federal regulators to authorize Pfizer’s COVID-19 vaccine for children as young as 6 months.
How a drug used to treat parasites for decades became the hot and controversial drug of the pandemic
Here's a look at the latest COVID-19 numbers for Ohio.
Israel is a vaccine star of the pandemic. It rolled out its initial jabs with great speed this time last year amid the deadly alpha wave. It saw off delta in the summer by pioneering booster shots. And, as omicron hit, it made fourth doses available to medics and the elderly.
The eyes are often called "the windows to the soul," but more often they can be a window to your health. Experts say that in particular, there's one subtle change that can tip you off to a problem involving your heart. They warn that if you notice this symptom in your eyes, it could signal high cholesterol—and the younger you are, the more likely it is to be the culprit. Read on to find out which ocular symptom could spell trouble for your heart health, and when you shouldn't worry.RELATED: Eati
Vaccine misinformation has played a huge role in the disappointing U.S. turnout, according to a former White House health policy adviser.
To users, these vapes are identical. But because of an obscure loophole, they skirt the FDA’s regulatory umbrella.
A new initiative to increase access to at-home COVID-19 tests will start in early spring, the government says
Lily James' fitness regime sounds intense. From her workouts to her diet plan, here's everything she did to get her body into shape. Lily James' weight…
Photo Illustration by Thomas Levinson/The Daily Beast/GettyRichard Powers’ Bewilderment was the most moving and prescient novel I read last year. In the book, an astrobiologist grapples with compounding losses: the death of his wife and the unraveling of his son, Robin; and the environmental degradation and mass extinction that envelops the planet. Before his demise, Robin begins an innovative treatment called Decoded Neurofeedback in which he enters an fMRI machine and learns how to mirror a br
The older you get, the more slowly you heal, and there are a number of reasons why. Westend61 via Getty ImagesI recently visited an 83-year-old patient in the hospital after EMTs rushed her to the ER with an infected leg wound. Her ordeal started inconspicuously when she bumped into the sharp edge of a table and developed a small cut. The patient’s wound didn’t close, but she ignored it until she woke up in pain one morning two weeks after first injuring her leg. Her daughter called 911 after no